Nuclear Medicine Clarification Act of 2025 (HR 2541)

Overview

The Nuclear Medicine Clarification Act of 2025 is a bill introduced in the U.S. House of Representatives that seeks to clarify the regulatory framework for the use of radioactive materials in medical applications. The primary goal of the legislation is to streamline the approval and oversight process for nuclear medicine procedures, while maintaining robust safety standards.

Key Provisions

The bill would make the following key changes:

1. Regulatory Oversight: The legislation transfers primary regulatory authority for nuclear medicine from the U.S. Nuclear Regulatory Commission (NRC) to the U.S. Food and Drug Administration (FDA). This shift in oversight is intended to better align nuclear medicine with the FDA's existing purview over drug and device approvals.

2. Approval Process: The bill establishes a new, expedited approval pathway for nuclear medicine drugs and devices. This streamlined process is designed to bring innovative nuclear medicine technologies to patients more quickly, while still ensuring thorough safety and efficacy reviews.

3. Licensing Requirements: The legislation simplifies the licensing requirements for healthcare providers to administer nuclear medicine procedures. It aims to reduce administrative burdens and increase access to these specialized treatments.

4. Reporting and Coordination: The bill mandates improved data collection and information sharing between the FDA, Centers for Medicare & Medicaid Services (CMS), and other relevant agencies. This is intended to enhance monitoring, oversight, and coordination of nuclear medicine utilization and safety.

Affected Stakeholders

The Nuclear Medicine Clarification Act would primarily impact the following groups:

• Patients: Increased access to innovative nuclear medicine treatments and procedures.
• Healthcare Providers: Simplified licensing requirements and regulatory oversight, potentially reducing administrative burdens.
• Pharmaceutical and Medical Device Manufacturers: Expedited approval pathways for new nuclear medicine products.
• Federal Agencies: Shift in regulatory authority from the NRC to the FDA, requiring coordination and data sharing.

Timeline and Next Steps

The bill was introduced in the House of Representatives on April 1, 2025 and has been referred to the House Energy and Commerce Committee for further consideration. If passed by the House and Senate, and signed into law by the President, the provisions of the Nuclear Medicine Clarification Act would take effect 180 days after enactment.